Zepbound (tirzepatide 15 mg) : The same active ingredient as Mounjaro, approved specifically for weight management, with similar results from the SURMOUNT trial data
Compared to DPP4 inhibitor, GLP-1RA use was associated with decreased risks of 30 outcomes, including respiratory failure, pneumonia, anemia, post-thrombotic sequelae, and bacterial infections, and increased risk of 13 outcomes, including sleep disturbances, nausea, vomiting, headaches, hypotension, sleep disturbances, and nephrolithiasis
PMID: 18926849 Giblin FJ
Then we place special contact applicators or paddles directly on your skin, sometimes securing them with comfortable straps to maintain perfect positioning throughout your session
Risk Factors Metabolic syndrome (strongest risk factor) increased waist circumference (obesity) insulin resistance elevations in: blood sugar cholesterol triglycerides blood pressure uric acid Diabetes (up to 75% of individuals with type 2 diabetes have NAFLD) Sleep apnea Gut microbiome effects Genetic factors Why is it important to address